IDEXX Laboratories

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade IDEXX Laboratories 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. 

CEO
Jonathan J. Mazelsky
CEOJonathan J. Mazelsky
Employees
11,000
Employees11,000
Headquarters
Westbrook, Maine
HeadquartersWestbrook, Maine
Founded
1983
Founded1983
Employees
11,000
Employees11,000

IDXX Key Statistics

Market cap
56.89B
Market cap56.89B
Price-Earnings ratio
56.64
Price-Earnings ratio56.64
Dividend yield
Dividend yield
Average volume
398.49K
Average volume398.49K
High today
High today
Low today
Low today
Open price
$707.29
Open price$707.29
Volume
0.00
Volume0.00
52 Week high
$769.98
52 Week high$769.98
52 Week low
$356.14
52 Week low$356.14

Stock Snapshot

The current IDEXX Laboratories(IDXX) stock price is $712.39, with a market capitalization of 56.89B. The stock trades at a price-to-earnings (P/E) ratio of 56.64.

IDEXX Laboratories(IDXX) stock opened on 2026-01-09 at $707.29. The price climbed to — and dipped to —.

The IDEXX Laboratories(IDXX)'s current trading volume is 0, compared to an average daily volume of 398.49K.

During the past year, IDEXX Laboratories(IDXX) stock moved between $356.14 at its lowest and $769.98 at its peak.

During the past year, IDEXX Laboratories(IDXX) stock moved between $356.14 at its lowest and $769.98 at its peak.

IDXX News

Simply Wall St 10h
Is IDEXX Turning Diagnostics Momentum Into a More Durable Investment Narrative?

IDEXX Laboratories recently prepared to release its fiscal Q4 2025 results, with analysts highlighting ongoing profit strength supported by its Companion Animal...

Is IDEXX Turning Diagnostics Momentum Into a More Durable Investment Narrative?
Benzinga 23h
Palo Alto, Capital One Financial, IDEXX Laboratories And More: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, named Palo Alto Networks, Inc. (NASDAQ:...

Palo Alto, Capital One Financial, IDEXX Laboratories And More: CNBC's 'Final Trades'
Simply Wall St 2d
Idexx Laboratories Valuation Check As Earnings Optimism Builds On Diagnostics Growth

Investor attention is turning to IDEXX Laboratories (IDXX) as the company heads into its fiscal fourth quarter earnings release, with expectations for continued...

Idexx Laboratories Valuation Check As Earnings Optimism Builds On Diagnostics Growth

Analyst ratings

67%

of 18 ratings
Buy
66.7%
Hold
27.8%
Sell
5.6%

People also own

Based on the portfolios of people who own IDXX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.